Please login to the form below

Not currently logged in
Email:
Password:

Kyndrisa

This page shows the latest Kyndrisa news and features for those working in and with pharma, biotech and healthcare.

Santhera facing long delay for muscular dystrophy drug in US

Santhera facing long delay for muscular dystrophy drug in US

In recent months the FDA has rejected BioMarin's exon-skipping therapy Kyndrisa (drisapersen) - which has now been abandoned after also being turned down by the EMA - as well as PTC

Latest news

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics